Resultado da Busca
Há 5 dias · A Accolade, uma proeminente empresa de saúde, compartilhou seus resultados financeiros do primeiro trimestre de 2025, destacando um crescimento de receita de 18% ano a ano, atingindo US$ 110,5 milhões. Apesar de um mercado de saúde desafiador, a empresa manteve o crescimento e a lucratividade ...
Há 4 dias · Accolade is now awarded a Hold rating as opposed to a Buy previously. The company's near-term financial prospects are mixed as per its full-year guidance, and the stock is reasonably valued.
Há 4 dias · Accolade Revenues and Earnings Beat Expectations. Revenue exceeded analyst estimates by 5.0%. Earnings per share (EPS) also surpassed analyst estimates by 27%. Looking ahead, revenue is forecast ...
Há 5 dias · A high-level overview of Accolade, Inc. (ACCD) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Há 5 dias · Accolade was the first and only company in our category to reach the public markets. We are now demonstrating scale in growth and profitability that reinforces our standing as the leader in the...
Há 6 dias · Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives.
Há 5 dias · Accolade Q1 2025 Earnings Preview Earnings week ahead: FedEx, Nike, Carnival, Micron, BlackBerry, Walgreens Boots, and more Accolade GAAP EPS of -$0.10 in-line, revenue of $124.8M beats by $0.88M
